These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 21885079

  • 1. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.
    Clark KM, Johnson JB, Kock ND, Mizel SB, Parks GD.
    Virology; 2011 Oct 25; 419(2):97-106. PubMed ID: 21885079
    [Abstract] [Full Text] [Related]

  • 2. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
    Kaufman DR, Goudsmit J, Holterman L, Ewald BA, Denholtz M, Devoy C, Giri A, Grandpre LE, Heraud JM, Franchini G, Seaman MS, Havenga MJ, Barouch DH.
    J Virol; 2008 Jul 25; 82(14):6829-37. PubMed ID: 18448519
    [Abstract] [Full Text] [Related]

  • 3. Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.
    Braxton CL, Puckett SH, Mizel SB, Lyles DS.
    J Virol; 2010 Apr 25; 84(7):3552-61. PubMed ID: 20089648
    [Abstract] [Full Text] [Related]

  • 4. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates.
    Hooper JW, Custer DM, Thompson E.
    Virology; 2003 Feb 01; 306(1):181-95. PubMed ID: 12620810
    [Abstract] [Full Text] [Related]

  • 5. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
    Berhanu A, Wilson RL, Kirkwood-Watts DL, King DS, Warren TK, Lund SA, Brown LL, Krupkin AK, Vandermay E, Weimers W, Honeychurch KM, Grosenbach DW, Jones KF, Hruby DE.
    J Virol; 2008 Apr 01; 82(7):3517-29. PubMed ID: 18199639
    [Abstract] [Full Text] [Related]

  • 6. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge.
    Hooper JW, Custer DM, Schmaljohn CS, Schmaljohn AL.
    Virology; 2000 Jan 20; 266(2):329-39. PubMed ID: 10639319
    [Abstract] [Full Text] [Related]

  • 7. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.
    Galmiche MC, Goenaga J, Wittek R, Rindisbacher L.
    Virology; 1999 Feb 01; 254(1):71-80. PubMed ID: 9927575
    [Abstract] [Full Text] [Related]

  • 8. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.
    Pulford DJ, Gates A, Bridge SH, Robinson JH, Ulaeto D.
    Vaccine; 2004 Sep 03; 22(25-26):3358-66. PubMed ID: 15308360
    [Abstract] [Full Text] [Related]

  • 9. Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.
    Paran N, Lustig S, Zvi A, Erez N, Israely T, Melamed S, Politi B, Ben-Nathan D, Schneider P, Lachmi B, Israeli O, Stein D, Levin R, Olshevsky U.
    Virol J; 2013 Jul 10; 10():229. PubMed ID: 23842430
    [Abstract] [Full Text] [Related]

  • 10. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.
    Golden JW, Josleyn MD, Hooper JW.
    Vaccine; 2008 Jun 25; 26(27-28):3507-15. PubMed ID: 18485547
    [Abstract] [Full Text] [Related]

  • 11. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin.
    Bell E, Shamim M, Whitbeck JC, Sfyroera G, Lambris JD, Isaacs SN.
    Virology; 2004 Aug 01; 325(2):425-31. PubMed ID: 15246280
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D, Phan S, DiStefano DJ, Citron MP, Callahan CL, Indrawati L, Dubey SA, Heidecker GJ, Govindarajan D, Liang X, He B, Espeseth AS.
    J Virol; 2017 Jun 01; 91(11):. PubMed ID: 28298602
    [Abstract] [Full Text] [Related]

  • 14. Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein.
    Kaever T, Meng X, Matho MH, Schlossman A, Li S, Sela-Culang I, Ofran Y, Buller M, Crump RW, Parker S, Frazier A, Crotty S, Zajonc DM, Peters B, Xiang Y.
    J Virol; 2014 Oct 01; 88(19):11339-55. PubMed ID: 25031354
    [Abstract] [Full Text] [Related]

  • 15. Modified Vaccinia Virus Ankara Can Induce Optimal CD8+ T Cell Responses to Directly Primed Antigens Depending on Vaccine Design.
    Wong YC, Croft S, Smith SA, Lin LCW, Cukalac T, La Gruta NL, Drexler I, Tscharke DC.
    J Virol; 2019 Nov 01; 93(21):. PubMed ID: 31375596
    [Abstract] [Full Text] [Related]

  • 16. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.
    Davies DH, McCausland MM, Valdez C, Huynh D, Hernandez JE, Mu Y, Hirst S, Villarreal L, Felgner PL, Crotty S.
    J Virol; 2005 Sep 01; 79(18):11724-33. PubMed ID: 16140750
    [Abstract] [Full Text] [Related]

  • 17. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.
    Fogg C, Lustig S, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B.
    J Virol; 2004 Oct 01; 78(19):10230-7. PubMed ID: 15367588
    [Abstract] [Full Text] [Related]

  • 18. A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice.
    Delaney KN, Phipps JP, Johnson JB, Mizel SB.
    Viral Immunol; 2010 Apr 01; 23(2):201-10. PubMed ID: 20374000
    [Abstract] [Full Text] [Related]

  • 19. Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators.
    Sumner RP, Ren H, Ferguson BJ, Smith GL.
    Vaccine; 2016 Sep 14; 34(40):4827-34. PubMed ID: 27544585
    [Abstract] [Full Text] [Related]

  • 20. Protection of mice against the highly pathogenic VVIHD-J by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity.
    Bissa M, Quaglino E, Zanotto C, Illiano E, Rolih V, Pacchioni S, Cavallo F, De Giuli Morghen C, Radaelli A.
    Antiviral Res; 2016 Oct 14; 134():182-191. PubMed ID: 27637905
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.